Novavax, Inc. (NASDAQ:NVAX) announced the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over.
What Happened: The FDA considers the recommendations of VRBPAC when making decisions on EUA.
